Taysha Gene Therapies, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Dallas, TX
TSHA chart
What traders are saying about $TSHA
Latest postsTaysha Gene Therapies, Inc. news
- Taysha Gene Therapies, Inc. expected to post a loss of 13 cents a share - Earnings Preview
TradingView ·
- 3 Gene Editing Stocks Retail Investors Are Watching After BioAdvance
Yahoo Finance ·
- Taysha Gene Therapies, Inc. (TSHA) Stock Price, News, Quote & History
Yahoo! Finance Canada ·
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance ·
- Taysha Gene Therapies plans to release third quarter 2026 earnings and corporate update
Traders Union ·
- Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
Yahoo Finance ·
- Taysha Gene Therapies to Release Third Quarter 2026
GlobeNewswire ·
- Taysha is developing a gene therapy for Rett syndrome. Its quarterly results are due Nov. 12.
Stock Titan ·
- Taysha Gene Therapies (TSHA) Stock Looks Rich Against Book Value
Yahoo Finance ·
- Does Early Rett Trial Success Change The Bull Case For Taysha Gene Therapies (TSHA)?
Yahoo Finance ·
- Taysha Gene Therapies (TSHA) Stock May Be Above Fair Value On Book Value
Yahoo Finance ·
- Taysha Gene Therapies (TSHA) Faces A Split Valuation Debate, Is It Really 66% Below Fair Value?
Yahoo Finance ·
Taysha Gene Therapies, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $9.8M | $8.3M | $15.5M | $2.5M |
| Net income | -$109.0M | -$89.3M | -$111.6M | -$166.0M |
| Diluted EPS | $-0.34 | $-0.36 | $-0.96 | $-3.78 |
| Total assets (year end) | $343.3M | $160.4M | $172.7M | $126.3M |
| Cash and equivalents (year end) | $319.8M | $139.0M | $143.9M | $87.9M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Taysha Gene Therapies, Inc.
- Ticker
- TSHA (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Dallas, TX
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1806310
Frequently asked questions
What exchange is Taysha Gene Therapies, Inc. listed on?
Taysha Gene Therapies, Inc. trades on the Nasdaq under the ticker symbol TSHA.
What industry is Taysha Gene Therapies, Inc. in?
Taysha Gene Therapies, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Taysha Gene Therapies, Inc. headquartered?
Taysha Gene Therapies, Inc.'s business address on file with the SEC is in Dallas, TX.
When does Taysha Gene Therapies, Inc.'s fiscal year end?
Taysha Gene Therapies, Inc.'s fiscal year ends on December 31.
How much revenue did Taysha Gene Therapies, Inc. report?
Taysha Gene Therapies, Inc. reported $9.8M in revenue for calendar year 2025, according to its SEC filings.